New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular ...

Discover how AI-driven blood testing is revolutionizing diagnostics by offering personalized health insights and consolidating tests.

Blueprint Medicines’ solid tumor med BLU-222 is back from the drawing board after the FDA lifted a partial clinical hold that has been in place since mid-February. The phase 1/2 VELA trial is back on ...

T cell therapies have revolutionized cancer treatment—but so far, their success has been largely limited to blood cancers.